Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab [0.03%]
Andrea Casadei-Gardini,Terry Cheuk-Fung Yip,Alessandro Vitale et al.
Andrea Casadei-Gardini et al.
Background and aims: Atezolizumab plus bevacizumab (A+B) and STRIDE (tremelimumab plus durvalumab) represent two of the approved first-line immunotherapy strategies for unresectable hepatocellular carcinoma (HCC). As no h...
Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank [0.03%]
Elie Rassy,Suzette Delaloge,Thérèse Truong et al.
Elie Rassy et al.
Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers. Earlier identification through improved risk prediction modelling represents a promising strategy for improving PDAC outcomes. ...
Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686] [0.03%]
Sarah Blocker,Diana Kim,Courtney C Cavalieri et al.
Sarah Blocker et al.
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP) [0.03%]
Aziz Zaanan,Juliette Palle,Florence Renaud et al.
Aziz Zaanan et al.
Introduction: The updated edition of the French intergroup guidelines for the management of patients with gastric and gastroesophageal junction adenocarcinoma is a collaborative work of several national medical societies,...
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours [0.03%]
一项I期剂量递增研究：评估OSE-279（抗PD-1单克隆抗体）在晚期实体瘤患者中的安全性和药代动力学及药效学特征
Marie Robert,Nuria Kotecki,Carlos Gomez-Roca et al.
Marie Robert et al.
Background: OSE-279 is a high affinity humanized monoclonal bivalent antibody against PD-1 with potent antitumor activity in vivo in syngeneic non-clinical models. ...
From bench to byte: A UK perspective on data-driven cancer research [0.03%]
从工作台到字节：英国人在数据驱动型癌症研究方面的看法
Sarah K Wooller,Andrew Blake,Martin McCabe et al.
Sarah K Wooller et al.
Cancer research is undergoing a profound transformation driven by the rapid expansion of clinical, genomic, imaging, and real-world data. As Europe prepares for the implementation of the European Health Data Space (EHDS), the ability of hea...
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma [0.03%]
阿特珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的长期生存影响因素分析
Pei-Chang Lee,Alessio Cortellini,Bernardo Stefanini et al.
Pei-Chang Lee et al.
Background: Despite the proven superiority against sorafenib, atezolizumab plus bevacizumab (A+B) lacks long-term efficacy data in unresectable hepatocellular carcinoma (uHCC). This study assessed clinicopathologic factor...
An open-label, two-cohort, phase 1a/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma [0.03%]
一项开放标签、两组、 Ib/II期研究：每周注射盐酸伊利替康脂质体与长春瑞滨和替莫唑胺(NALIRI-VT)联合治疗晚期尤因肉瘤患者
Yuwei Zhao,Jie Xu,Yiyang Yu et al.
Yuwei Zhao et al.
Purpose: To determine the recommended phase II dose (RP2D), safety, and preliminary efficiency of liposomal irinotecan combined with vincristine and temozolomide (NALIRI-VT) in children and adult with relapsed/refractory ...
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy [0.03%]
LAURA研究的患者报告结果：对于接受过确定性化疗和放疗后的不可切除III期EGFR突变非小细胞肺癌患者的奥希替尼治疗
Edurne Arriola,Ignacio Casarini,Mustafa Özgüroğlu et al.
Edurne Arriola et al.
Background: The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with osimertinib versus place...
Incidence and outcome of oropharynx carcinoma in Denmark 1986-2020: A population based DAHANCA study [0.03%]
丹麦1986-2020年口咽癌的发病率和预后：基于人口的DAHANCA研究
Pernille Lassen,Jan Alsner,Claus Andrup Kristensen et al.
Pernille Lassen et al.
Purpose: The global incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) varies widely. Long-term, population-based studies with consistent treatment protocols are essential for understanding geographic ...